Acquired myeloma-associated Type III hyperlipidaemia treated by nonmyeloablative HLA-identical sibling allogeneic stem cell transplant using a donor with essential thrombocythaemia (ET): Evidence of engraftment without manifestation of ET in recipient [2]

Bone Marrow Transplantation

Volumn 35, Issue 12, 2005, Pages 1213-1214

  Chee, L ^a   Spearing, R L ^a   Morris, C M ^b   McDonald, M ^b   Hanrahan, V ^c   Ebbett, A ^a   Scott, R ^a   Florkowski, C ^c   Walmsley, T ^c   Patton, W N ^a  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c CANTERBURY HEALTH LABORATORIES   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANAGRELIDE; APOLIPOPROTEIN E; BCR ABL PROTEIN; CHOLESTEROL; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; HIGH DENSITY LIPOPROTEIN; HLA ANTIGEN; HYDROXYUREA; IMMUNOGLOBULIN G; IMMUNOGLOBULIN LAMBDA CHAIN; INTERMEDIATE DENSITY LIPOPROTEIN; LIPID; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THALIDOMIDE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; VINCRISTINE;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CASE REPORT; CHROMOSOME ANALYSIS; DISEASE ASSOCIATION; DONOR; DRUG WITHDRAWAL; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; HYPERLIPIDEMIA; INFORMED CONSENT; KARYOTYPE 47,XYY; LETTER; LYMPHOCYTE TRANSFUSION; MALE; MEDICAL ETHICS; MULTIPLE MYELOMA; NONMYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ELECTROPHORESIS; RECIPIENT; RELAPSE; REMISSION; SAFETY; SIBLING; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; WHOLE BODY RADIATION;

FEMALE; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYPERLIPOPROTEINEMIA TYPE III; MALE; MIDDLE AGED; MULTIPLE MYELOMA; SIBLINGS; THROMBOCYTHEMIA, HEMORRHAGIC; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 21244457610     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704973     Document Type: Letter

References (8)

1. Cortese C, Lewis B, Miller NE et al. Myelomatosis with Type III hyperlipoproteinemia: clinical and metabolic studies. N Engl J Med 1982; 307: 79-83.
2. Feussner G, von Hodenberg E, Ziegler R. Atypical type III hyperlipoproteinemia in a patient with IgA myelomatosis. Klin Wochenschr 1990; 68: 526-532.
3. Hambrecht R, von Hodenberg E, Schuler G et al. Type III hyperlipoproteinemia in monoclonal IgM gammopathy. Deut Med Wochenschr 1991; 116: 1710-1714.
4. Spagnuolo V, Motti C, Pujia A et al. Dyslipoproteinemia and monoclonal gammopathy: a case report. Ann Ital Med Intern 1996; 11: 204-207.
5. Johnston JD, Lumb PJ, Wierzbicki AS. Hyperlipidaemia in association with benign paraproteinaemia. Ann Clin Biochem 1997; 34: 697-699.
6. Nozaki S, Ito Y, Nakagawa T et al. Autoimmune hyperlipidemia with inhibitory monoclonal antibodies against low density lipoprotein binding to fibroblasts in a case with multiple myeloma. Intern Med 1997; 36: 920-925.
7. Fonseca R, Barlogie B, Bataille R et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004; 64: 1546-1558.
8. Perez-Simon JA, Garcia-Sanz R, Tabernero MD et al. Prognostic value of numerical chromosome aberrations in multiple myeloma: a FISH analysis of 15 different chromosomes. Blood 1998; 91: 3366-3371.